We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A090: Hemodynamic response to bolus iv fenoldopam in hypertensive patients is independent of baseline heart rate.
- Authors
Gardezi, A.; Sunthornyothin, S.; Butler, R.; Ellis, D.; Pool*, J.; Taylor*, A.
- Abstract
Continuous iv infusion of the selective DA-1 agonist, fenoldopam (F) produces sustained blood pressure (BP) reductions and modest heart rate (HR) increases in hypertensive (HT) patients. In some clinical settings rapid but transient reductions in BP with iv bolus injections of F may be desirable but the hypotensive effect may be exaggerated by β-blockade. As part of a larger blinded trial we examined the hemodynamic effect of increasing bolus doses of F (3 to 300 μg) given iv to 15 patients with stage I-II HT randomized to receive either placebo or atenolol 100 mg/d for 1 week. After 1 week of the alternative treatment, bolus iv F was repeated. Since the trial is still blinded, patients were arbitrarily divided into low (L) and high (H) groups based on resting heart rate (HR) before each test. Pre-F systolic BP was comparable in the two groups (170 ± 6 vs 165 ± 8 mmHg, mean ± SEM) while HR was significantly greater in H (68 ± 2 vs 58 ± 2 bpm, p < 0.001), as expected. Despite these baseline differences, regression characteristics of the bolus dose-dependent BP reduction and HR increase were virtually identical in the two treatment periods. We conclude that the bolus dose-response to F is predictable and that a lower resting HR, probably due to oral β-blocker, does not influence the hemodynamic response to iv bolus fenoldopam.Am J Hypertens (2000) 13, 145A-145A; doi:S0895-7061(00)00623-3
- Publication
American Journal of Hypertension, 2000, Vol 13, p145A
- ISSN
0895-7061
- Publication type
Article
- DOI
10.1016/S0895-7061(00)00623-3